Camargo Expands, Opens New Office in The Research Triangle Park
Camargo Pharmaceutical Services, an end-to-end drug development company specializing in the 505(b)(2) process, has announced today its expansion into The Research Triangle Park (RTP) with the opening of a new office. The new location will pave the way for additional opportunities and service offerings, as well as streamlining client service.
Camargo’s decision to expand its reach to the east coast, specifically RTP, abides with the Company’s overall growth goals and global service coverage. RTP, the largest research park in the nation, is a 7,000-acre development that is home to more than 170 companies.
Camargo is focused on global drug development through the 505(b)(2) process and provides a full spectrum of services from discovery through each phase of clinical development.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
